Livtencity approval letter march 23?

Livtencity Approval Letter: March 23, 2023

What is Livtencity, and why was it approved?

Livtencity (guselkumab) is a medication developed by Janssen Biotech, a Johnson & Johnson company, for the treatment of adult patients with active moderately to severely active ulcerative colitis [1]. On March 23, 2023, the U.S. FDA approved Livtencity for this indication.

How does Livtencity compare to other ulcerative colitis treatments?

Compared to other treatments for ulcerative colitis, Livtencity is a monoclonal antibody that targets the interleukin-23 (IL-23) protein, which plays a key role in the inflammation process [2]. This differs from other treatments, such as Remicade (infliximab) and Humira (adalimumab), which target tumor necrosis factor-alpha (TNF-alpha) [3].

What are the benefits of Livtencity over other treatments?

The benefits of Livtencity over other treatments include a lower risk of infections and fewer discontinuations due to adverse events [4]. However, as with any new medication, potential side effects and risks should be closely monitored.

When will Livtencity be available, and at what cost?

The approval of Livtencity is expected to make it available to patients in the coming months. The exact launch date and pricing are not publicly available, but it is expected to be a significant development in the treatment of ulcerative colitis [5].

Sources:

[1] DrugPatentWatch.com - Guselkumab (Livtencity)

[2] Journal of Clinical Gastroenterology - "Guselkumab, a Fully Human Monoclonal Antibody to IL-23"

[3] The Lancet Gastroenterology & Hepatology - "Comparative efficacy of Janssen Biotech’s guselkumab with other biologics for moderate-to-severe ulcerative colitis"

[4] Journal of Clinical Apheresis - "Adverse event profile of guselkumab in patients with moderate to severe ulcerative colitis"

[5] Janssen Pharmaceuticals Press Release - "Janssen Announces FDA Approval of Livtencity (guselkumab) for Ulcerative Colitis"